However, Amgenâ€™s mature drugs like Enbrel, Aranesp, Epogen, Neupogen and Neulasta declined due to an array of branded and generic competitors.Nonetheless, Amgen expects fluctuations in quarterly revenues and earnings as long as the pandemic continues due to uncertainty around the timing of the recovery.